NEW YORK --(BUSINESS WIRE)--Aug. 11, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on August 9, 2023 , the company granted (i) a non-statutory stock option to purchase 90,000
Announces IND Clearance for CDC7 Inhibitor SGR-2921, Continued Progress for MALT1 Inhibitor SGR-1505 Delivers Second Quarter Total Revenue of $35.2 Million Raises 2023 Software Revenue Guidance and Reduces Drug Discovery Guidance NEW YORK --(BUSINESS WIRE)--Aug. 2, 2023-- Schrödinger, Inc.
NEW YORK --(BUSINESS WIRE)--Jul. 20, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on July 14, 2023 , the company granted (i) non-statutory stock options to purchase 10,250
NEW YORK --(BUSINESS WIRE)--Jul. 19, 2023-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its second quarter 2023 financial results on Wednesday, August 2, 2023 , after the financial markets
NEW YORK --(BUSINESS WIRE)--Jun. 22, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on June 16, 2023 , the company granted (i) non-statutory stock options to purchase 14,325
NEW YORK --(BUSINESS WIRE)--Jun. 1, 2023-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare
NEW YORK --(BUSINESS WIRE)--May 26, 2023-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference .
NEW YORK --(BUSINESS WIRE)--May 25, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on May 19, 2023 , the company granted (i) non-statutory stock options to purchase 7,660
Delivered First Quarter Total Revenue of $64.8 Million , Driven by Strong Drug Discovery Revenue of $32.6 Million Reports First Subjects Enrolled in Both Ongoing Phase 1 Study of MALT1 Inhibitor SGR-1505 and Newly Initiated Phase 1 Study in Healthy Subjects Cash Position Significantly Strengthened
– Report Highlights Accomplishments in 2022 and Outlines Material Topics Through the Concept of Shared Value – NEW YORK --(BUSINESS WIRE)--Apr. 27, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered,